PDCD1 and cancer: Among the various immunotherapeutic approaches, blockade of immune checkpoint proteins, specifically PD-1/PD-L1 (CD279/CD274), has shown impressive effectiveness in various cancer types, including melanoma (Hamid et al. 2013), lung cancer (Reck et al. 2016), and colorectal cancer (Hu et al. 2022).